Combating Agent X: Accelerating Global Vaccine Production Against New Pandemic Threats

Similar documents
Emerging Infectious Disease Threats. Margaret A. Hamburg M.D. Foreign Secretary, U.S. National Academy of Medicine

Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS

Biotechnology and Biosecurity: Enhancing Security in an Increasingly Unsecure World

A conversation with Michael Osterholm on July 30, 2013 about pandemics

Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS

Preventing disease Promoting and protecting health

EPIDEMICS AND PANDEMICS: PREDICTION, PREVENTION, CONTROL?

Identifying, Preparing for & Reducing Pandemic Risk

Confronting infectious diseases and the role of vaccination: A global perspective KATE ANTEYI. MD, MPH, MBA

Acute respiratory illness This is a disease that typically affects the airways in the nose and throat (the upper respiratory tract).

The Influence of Zoonotic Diseases on Human Health

Emerging & re-emerging infections on the African Continent-the Public Health Aspect: Is Africa Prepared?

Risks of Emerging Infectious Diseases in ASEAN. Prasit Palittapongarnpim, M.D. Department of Microbiology, Faculty of Science, Mahidol University

Global Catastrophic Biological Risks

WHO: Forum Issue #02 Student Officer Position:

When infections go viral Zika Virus

Emerging global health threats of animal origin

Killer Viruses: The Why and The How. Amesh Adalja

On behalf of the Infectious Diseases Society of America (IDSA), I offer testimony in

CIDRAP Leadership Forum Infectious Disease BRIEFING August 17, 2016

The Threat of Agroterrorism and Zoonotic Diseases in the United States

IS THE UK WELL PREPARED FOR A REPEAT OF THE 1918 INFLUENZA PANDEMIC?

Blueprint for R&D preparedness and response to public health emergencies due to highly infectious pathogens WORKSHOP ON PRIORITIZATION OF PATHOGENS

Gene Vaccine Dr. Sina Soleimani

Countries initially targeted: Bangladesh, Mongolia, Myanmar, Nepal, Lao People s Demoncratic Republic and Pakistan.

1966 CDC assessment of US Health

Influenza: The Threat of a Pandemic

INTERfering and Co-Evolving Prevention and Therapy (INTERCEPT) Proposers Day

Advanced Lecture on One Health

Vaccines: Reaching for higher branches after the low hanging fruit has been picked

Pandemic Influenza Preparedness

Synthetic Genomics and Its Application to Viral Infectious Diseases. Timothy Stockwell (JCVI) David Wentworth (JCVI)

A UNIQUE NETWORK OF EXPERTISE DEDICATED TO THE FIGHT AGAINST INFECTIOUS DISEASES

PARALLEL SESSION 2.4

Chapter 14 Part One Biotechnology and Industry: Microbes at Work

VACCINE ENGINEERING Dr.T.V.Rao MD

Lecture 2 Evolution in action: the HIV virus

7th Mena Influenza Stakeholders Meeting. WHO Influenza Strategy Development and Vaccine-related Research Priorities

EC research and innovation strategy and actions

CE Unit. Viruses and Vaccines

5.4.8 Pandemic Disease

Topic 7 - Commonality

Pandemic Influenza Preparedness and Response

Experiences on Workforce Development in Other Regions

Centers for Disease Control and Prevention (CDC) FY 2009 Budget Request Summary

ENHANCING AFRICA S PUBLIC HEALTH RESPONSE THROUGH INNOVATION AND PARTNERSHIPS

One World One Health: An Economic Perspective

Introduction. In the past 15 years, several technological advancements have open new perspectives and applications in the field of vaccinology.

2013 Disease Detectives

Devon Community Resilience. Influenza Pandemics. Richard Clarke Emergency Preparedness Manager Public Health England South West Centre

VIRUSES. Biology Applications Control. David R. Harper. Garland Science Taylor & Francis Group NEW YORK AND LONDON

Center for Global Health. CDC Global Health Saving Lives Overseas, Protecting Americans at Home

Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention. June 18, 2015 NIBSC

Linking Pandemic Influenza Preparedness with Bioterrorism Vaccination Planning

LECTURE topics: 1. Immunology. 2. Emerging Pathogens

Disease Prevention, Detection & Response During Public Health Emergencies

4.3.9 Pandemic Disease

Lesson 20 Study Guide: Medical Biotechnology Pandemic Flu & Emergent Disease

Mapping the Global Virome. Making the Unknown Known. And the World Safe From a Future of Viral Threats

Financing international collective action for epidemic & pandemic preparedness


2013 NEHA AEC July 9 11, One Health and All-Hazards: the New Environmental Health. Want this on you?

Cover Page. The handle holds various files of this Leiden University dissertation

J. A. Sands, 21 October 2013 Lehigh University

Better Training for Safer Food BTSF

Vaccines contribution to Europe s future

PANDEMIC INFLUENZA IN THE WORKPLACE

2000 and Beyond: Confronting the Microbe Menace 1999 Holiday Lectures on Science Chapter List

Dr. Alejandro Schudel Fundación PROSAIA Argentina. 17 th IMS World Meat Congress Cape Town, South Africa, 7-10 September 2008

WORLD BANK RESPONSE TO INFLUENZA A(H1N1) Rakesh Nangia Director, Strategy & Operations Human Development Network

Assessing economic vulnerability to emerging infectious disease outbreaks: Ebola versus Zika

Biosecurity: Enhancing Security in an Increasingly Unsecure World

CE Unit 7. Viruses and Vaccines

Center for Biologics Evaluation and Research

Broadly protective influenza vaccines for pandemic preparedness. Suresh Mittal Department of Comparative Pathobiology Purdue University

Managing cost considerations and access to technology for cost effective vaccine manufacture in developing countries.

Biomedical Engineering for Global Health. Lecture 10 HIV/AIDS vaccine development

Global Challenges of Pandemic and Avian Influenza. 19 December 2006 Keiji Fukuda Global influenza Programme

Biosecurity: Enhancing Security in an Increasingly Complex World

The Economics of Zoonotic Diseases in China

Suggested Exercises and Projects 395

Planning Informed by Epidemiological Simulation: The Geography of Avian Flu in Nigeria

Developing the next generation of infection and immunity leaders. The Peter Doherty Institute for Infection and Immunity

Running head: INFLUENZA VIRUS SEASON PREPAREDNESS AND RESPONSE 1

Media centre Global infectious disease surveillance

Progress report on emerging and re-emerging diseases including dengue and dengue haemorrhagic fever

U.S. Readiness for Pandemics

Antimicrobial resistance Fact sheet N 194 Updated April 2014

Medical Officer of Health Medical Director, Travel Health and Tropical Medicine Services Winnipeg Regional Health Authority

2.1 VIRUSES. 2.1 Learning Goals

September 7, Dear Director Mulvaney:

Enhancing Public Health Disease Surveillance, Detection, Diagnosis and Containment Capability in Nigeria.

DRAFT WGE WGE WGE WGE WGE WGE WGE WGE WGE WGE WGE WGE WGE WGE GETREADYNOWGE GETREADYNOWGE GETREADYNOWGE GETREADYNOWGE.

Ebola Epidemic in Coastal West Africa Overall Situation

CIDRAP Leadership Forum Infectious Disease BRIEFING

Vaccine Design: A Statisticans Overview

Viral vaccines. Lec. 3 أ.د.فائزة عبد هللا مخلص

Global Health Security: Preparedness and Response: can we do better and stay safe?

Addressing climate change driven health challenges in Africa

What's the future for animal vaccines?

Transcription:

Combating Agent X: Accelerating Global Vaccine Production Against New Pandemic Threats Dr. George Poste Chief Scientist, Complex Adaptive Systems Initiative and Del E. Webb Chair in Health Innovation Arizona State University george.poste@asu.edu www.casi.asu.edu From Omics to Action: Exponential Medicine 2016 Conference October 9, 2016 Hotel del Coronado, San Diego

The Social, Economic and Political Impact of Epidemic and Epizootic Disease Plague of Athens Bubonic Plague Small Pox Pandemic Influenza Foot and Mouth Disease Rinderpest African Swine Fever Rabies 2

A Decade of New and Resurgent Viral Threats SARS-CoV MERS-CoV West Nile Yellow Fever Dengue Chikungunya Ebola Zika 3

Expanded Horizons for Preparedness Against Infectious Disease global connectivities and faster spread new technologies: gene editing and synthetic organisms bioterrorism and dual-use technologies

WHAT S NEXT?

Recognition of the Importance of Zoonotic Diseases as Human Health Threats pandemic (avian) influenza HIV West Nile virus MERS? Ebola virus bush meat food chain Zika virus what s out there?

Urbanization and Mega-Cities in Developing Countries and the Increased Threat of Exotic Zoonotic Diseases High Population Density With Inadequate Biosurveillance Major Gaps in Health Infrastructure and Disease Reporting Expanded Eco-niches and New Zoonotic Exposures/Risks

Anthropogenic Effects on Ecosystem Stability and Altered Patterns of Infectious Diseases famine contaminated water desertification depletion of natural resources climate change and new vector ranges new vulnerabilities

Phylogenetic Maps of Viral Evolution Understanding Drift and Shift in Immunogenic Proteins Influenza Virus Zika

The Core Triad in Combating Infectious Diseases global biosurveillance preparedness protection threat spectrum monitoring detection dynamics robust public health capabilities resources training infrastructure investment counter-measures drugs vaccines quarantine/ vector control

Ebola in West Africa 2013: Underinvestment and Bureaucratic Sclerosis of International Public Health Responses to New Threats 26 December 2013 index case zero Emile Ouamouno (Meliandou, Guinea) 21 March 2014 first report by WHO-AFRO region 8 August 2014 WHO declaration of Public Health Emergency of International Concern

Notice the Resemblance? Hygiene and Quarantine as the Only Protection Absent Drugs or Vaccines Bubonic Plague Physician 15th Century Ebola, Liberia 21 st Century

Combating Agent X: Speed Saves Lives the imperative for faster detection and accelerated protection counter-measures current R&D cycles are too slow to counter global epidemic/pandemic threats diagnostic tests (Dx): 3-12 months vaccines (Vx): 3-10 years therapeutics (Rx) 8-15 years the greatest good for the largest number of people production volume and access cost vaccines trump drugs

Limitations and Challenges in Current Vaccine Production Identification of Immunizing Antigen(s) Manufacture Distribution efficacy safety speed scale access affordability lengthy R&D cycles (years) extended production cycles (months) constrained production volumes (millions vs billions for global population of doses)

The Three Eras of Vaccine Production Pasteurian Era intact organisms killed live, attenuated Recombinant DNA Era rdna expression/ purification of immunizing antigens Engineered Vector Era live DNA and RNA viral vectors for in vivo expression of immunizing antigens

Combating Agent X: The Urgent Need for Faster, Larger Scale Vaccine Production Convert 19th Century Pasteurian-Derivative Biological Production Methods to 21st Century Predictive Computational Design and Chemical Synthesis of Immunizing Antigens

Elucidation of the Molecular Design Rules for Immune Recognition of Peptides and Proteins self non-self Vaccinomics: The convergence of microbiology, genomics, immunology, computational analytics and synthetic chemistry

Mapping the Universe of 3-D Protein Structures: Linking Structure and Composition With Immunogenicity

Immune Recognition of Foreign Peptides and Proteins at the Molecular Level: Mapping Epitopes B lymphocyte antibody-mediated immunity Cytotoxic T lymphocyte-mediated immunity Immunogenicity of Non-Self Molecules Recognition of Specific Molecular Domains epitopes) by the Immune System Excision and Processing of Epitopes by Dendritic Cells and Presentation to B and T Cells

The Quest for Pan-Vaccines effective against multiple strains of the same virus HIV Influenza Zika cross-protection against related viruses dengue, Zika, Chikungunya A Crucial Clue: formation of broad neutralizing antibodies that protect against multiple strains

The Quest for a Universal Influenza Vaccine: Identification of Broad- (Multi-Strain) Neutralizing Antibodies From: K. J.L. Jackson and S. D. Boyd (2016) Cell 166, 532

Overlapping Epitopes in the Hemagglutinin (HA) Stem Domain for Antibodies Neutralizing Group 1 and 2 Influenza A Viruses HA Stem From: K. J.L. Jackson and S. D. Boyd (2016) Cell 166, 532

Understanding Commonalities in Epitope Design and Identification of Rules for Epitope Recognition by the Immune System Epitope Design Rules as the Foundation For Chemical Production of Synthetic Vaccines Application of Design Rules to Predict Epitopes in Agent X

Complementary In Silico and In Vivo Analysis of Virus Epitopes application of large scale computational and machine learning analytics to characterize commonalities in the structure and composition of epitopes in different viruses profiling of virus epitope peptides recognized by high affinity antibodies or T cell receptors

Combating Agent X: Conversion of Vaccine Technology From Biological Production to Synthetic Chemistry Master Reference Databank of Peptide and Protein Composition, 3-D Structure and Immunogenicity

Large Scale Computational and Machine Intelligence Analytics of Epitope Composition: Structure Rules for Immune Recognition

Combating Agent X: Predictive Design Rules for Recognition of Foreign Peptides and Proteins by the Immune System Agent X Genome Sequence identification of structural proteins and strain variation Agent X Proteome machine learning prediction of most likely immunogenic epitopes Chemical Synthesis of Candidate Vaccine Epitopes assay immunogenic safety/efficacy

Parallel Insights Into Epitope Structure By High Throughput Screening of Antibody Binding to Peptide Arrays

Immunosignatures: Comprehensive Profiling of Antibody Repertoires S. A. Johnston, K. Sykes, N. Woodbury: ASU Biodesign

Profiling Differential Patterns of Peptide Recognition by Antibodies Elicited by Different Infectious Agents Known Agent A Known Agent B Agent X

Sequencing of Immunosignature Peptides Recognized by High Affinity Antibodies and Synthesis as Candidate Vaccines Immunosignature of Agent X Sequence Cognate Peptides Synthesize Cognate Peptides and Assay Immunogenicity Potency

Peptide and Protein Engineering for Rational Design and Chemical Synthesis of Vaccines cryo-em technologies for rapid ID of 3-D structure backbone scaffolds and self-assembling structures to carry multiple epitopes optimize epitope presentation and recognition by MHC/HLA alleles incorporate additional peptide domains to stimulate release of immune-enhancing cytokines/lymphokines

The Global Landscape for Infectious and Parasitic Diseases society is ill-prepared to combat a novel pandemic threat (Agent X) comfort and complacency: out-of-sight: out-of-mind inadequate threat surveillance: what s out there major gaps in pandemic preparedness: from faster detection to robust counter-measures and control potential expansion of threat spectrum from new gene editing technologies and engineered organisms escalating vulnerabilities: rude shocks await

Conversion of Vaccine Technology from the Current Pasteurian-Pedigree of Biological Production to Chemical Production of Synthetic Epitope-Based Vaccines expand production volume to meet global protection needs expand production facilities via use of larger footprint of worldwide chemical facilities accelerated response for protection of global population or critical agricultural livestock economies against novel threats

A Philosophy for Robust Preparedness Against Existential Threats Politics is the art of the possible, the calculated science of survival Prince Otto von Bismarck Survival owes little to the art of politics, but everything to the calculated application of science. Professor Rudolph Virchow (in reply)